{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.75","upperLimit":"3.03","value":"2.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"561"}],"units":"Participants"}],"description":"Per the planned PK analysis, PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Eribulin plasma concentration data from this study were pooled from studies (NCT00069264, NCT00069277, NCT00326950, NCT00706095, NCT01000376, NCT01106248, NCT02171260, NCT00413192, NCT01458249, NCT03441360 and NCT01327885), and a population PK model was applied to the pooled dataset. The data presented are the CL parameter estimates, with Measure Type \"Number\" defining the eribulin PK model. They are population PK model predictions and have been estimated using non-linear mixed effects model.","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants who received eribulin mesilate intravenous infusion over the dose range 0.25 to 4.0 mg/m\\^2 in current study (E7389-G000-213) and studies (NCT00069264, NCT00069277, NCT00326950, NCT00706095, NCT01000376, NCT01106248, NCT02171260, NCT00413192, NCT01458249, NCT03441360 and NCT01327885).","id":"OG000","title":"Eribulin Mesilate - All Participants"}],"paramType":"NUMBER","populationDescription":"PK analysis set included all participants who had documented dosing history had at least one postdosing quantifiable drug concentration. Analysis population for this outcome measure included participants from current study E7389-G000-213 and from studies (NCT00069264,NCT00069277,NCT00326950,NCT00706095,NCT01000376,NCT01106248,NCT02171260, NCT00413192,NCT01458249,NCT03441360,NCT01327885).\"Overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 0.5-120 hours after eribulin infusion; Cycle 1 Day 8: pre-dose and at the end of the eribulin infusion (cycle length=21 days)","title":"Model Predicted Apparent Total Body Clearance (CL) of Eribulin","type":"SECONDARY","unitOfMeasure":"L/hr"}